Alaunos Therapeutics, Inc. (TCRT)
|52 Week Range||0.45-4.01|
|1y Target Est||-|
|DCF Unlevered||TCRT DCF ->|
|DCF Levered||TCRT LDCF ->|
|Debt / Equity||68.43%||Buy|
Upgrades & Downgrades
Latest TCRT news
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
3 May 2023
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeli...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
29 March 2023
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipe...
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
28 February 2023
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will ...
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
24 January 2023
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
18 January 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
After Plunging 42% in 4 Weeks, Here's Why the Trend Might Reverse for Ziopharm (TCRT)
30 November 2022
Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...
Alaunos Therapeutics Still Waiting For Home Run
21 November 2022
First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete res...
New Strong Buy Stocks for November 18th
18 November 2022
VIRC, TCRT, AINC, CWEN and WHF have been added to the Zacks Rank #1 (Strong Buy) List on November 18, 2022.
Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript
14 November 2022
Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive O...
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society f...
7 November 2022
HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster prese...
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >